1. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents;O'Connor;Anticancer Res,1997
2. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment;Fan;Clin. Cancer Res.,1998
3. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer;Chan;J. Clin. Oncol.,1999
4. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC;Nabholtz;Proc. Am. Soc. Clin. Oncol.,1999
5. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients with metastatic breast cancer (MBC);Nabholtz;Proc. Am. Soc. Clin. Oncol.,2001